Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results

Endocyte (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, provided an update on its corporate strategy and announced financial results for the fourth quarter and full year ending Dec. 31, 2017.

As quoted in the press release:

“Following a successful End of Phase 2 meeting with the FDA, we are excited to launch the VISION trial, a phase 3 registration trial of ¹⁷⁷Lu-PSMA-617 in patients with prostate cancer,” said Mike Sherman, president and CEO of Endocyte. “After extensive collaboration with prostate cancer specialists around the world, the robust and sophisticated VISION trial design will be attractive to patients and physicians when we begin enrollment in the second quarter of 2018.”

Click here to read the full press release.